Viridian CFO files amended tax-share disposition

Viridian Therapeutics Chief Financial Officer files an amended insider transaction report reflecting tax-related share withholding.

Rhea-AI Filing Summary

Viridian Therapeutics Chief Financial Officer files an amended insider transaction report reflecting tax-related share withholding. On the corrected Form 4/A, Seth Harmon is shown disposing of 2,031 shares of Viridian common stock on March 3, 2026 at $30.19 per share to cover tax obligations. Following this tax-withholding disposition, he beneficially owns 7,850 shares of common stock. The amendment updates both the number of shares and the price used to satisfy taxes, as well as the resulting total holdings, compared with the initial Form 4 filed on March 4, 2026.

Insider Trade Summary

Exercise Price or Tax Liability: 2,031 shares

Exercise Price or Tax Liability 1 txn

Insider Harmon Seth

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	2,031	$30.19	$61K

Holdings After Transaction: Common Stock — 7,850 shares (Direct)

Footnotes (1)

1. F1. This amendment corrects the number of shares and price sold to cover taxes on the initial Form 4 filed on March 4, 2026, as well as the resulting total number of shares beneficially owned following all transactions reported in the initial Form 4.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Viridian Therapeutics (VRDN) report for its CFO?

Viridian’s Chief Financial Officer Seth Harmon reported a tax-withholding disposition of 2,031 common shares on March 3, 2026 at $30.19 per share. This Form 4/A amends an earlier filing by correcting the share amount, price, and resulting total beneficial ownership after the transaction.

Why was a Form 4/A amendment filed for Viridian Therapeutics (VRDN)?

The Form 4/A was filed to correct the number of shares and price previously reported as sold to cover taxes. It also updates the total number of Viridian common shares Seth Harmon beneficially owns following all transactions disclosed in the initial March 4, 2026 Form 4.

How many Viridian Therapeutics (VRDN) shares does the CFO own after the amended transaction?

After the corrected tax-withholding disposition, Viridian’s Chief Financial Officer Seth Harmon beneficially owns 7,850 shares of common stock. This updated total reflects revisions to both the shares withheld for taxes and the price per share previously reported in the original Form 4 filing.

Was the Viridian Therapeutics (VRDN) CFO’s transaction an open-market sale?

No. The filing classifies the transaction with code “F,” indicating shares were disposed of to satisfy tax obligations. This tax-withholding disposition involves delivering shares to cover taxes, rather than an open-market sale initiated for portfolio or investment purposes by the officer.

What was the price used for the Viridian Therapeutics (VRDN) CFO’s tax-withholding shares?

The amended Form 4/A reports a price of $30.19 per share for the 2,031 Viridian common shares disposed to cover taxes. This corrected price, along with the revised share count, replaces the prior figures disclosed in the initial insider transaction report filed on March 4, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/09/2026 - 07:49 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Harmon Seth

(Last) (First) (Middle)

C/O VIRIDIAN THERAPEUTICS, INC.

221 CRESCENT STREET, SUITE 103A

(Street)

WALTHAM MA 02453

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Viridian Therapeutics, Inc.\DE [ VRDN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)
03/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		F		2,031(1)	D	$30.19	7,850(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This amendment corrects the number of shares and price sold to cover taxes on the initial Form 4 filed on March 4, 2026, as well as the resulting total number of shares beneficially owned following all transactions reported in the initial Form 4.

	/s/Jennifer Tousignant, Attorney-in-fact	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.